| pubmed-article:2644824 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2644824 | lifeskim:mentions | umls-concept:C0022661 | lld:lifeskim |
| pubmed-article:2644824 | lifeskim:mentions | umls-concept:C1524081 | lld:lifeskim |
| pubmed-article:2644824 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2644824 | pubmed:dateCreated | 1989-3-15 | lld:pubmed |
| pubmed-article:2644824 | pubmed:abstractText | Ten patients with chronic renal failure whose hypertension was controlled with triple drug therapy consisting of propranolol-hydralazine-furosemide were switched to the angiotensin-converting enzyme (ACE) inhibitor captopril for a period of 12 months. Control of hypertension was similar with both antihypertensive regimens. Clearance of inulin and of paraaminohippuric acid increased during the first 3 months of captopril therapy and remained stable thereafter. Moreover, the decline in the reciprocal of serum creatinine over time observed during triple drug therapy was arrested during therapy with the ACE inhibitor. If the salutary effects of captopril are sustained, the results obtained in the current studies would suggest that control of hypertension by ACE inhibition may be effective in slowing progression of renal failure. Future studies to answer this important question are necessary. | lld:pubmed |
| pubmed-article:2644824 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2644824 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2644824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2644824 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2644824 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:2644824 | pubmed:issn | 0272-6386 | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:RodicioJ LJL | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:RuilopeL MLM | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:MoralesJ MJM | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:RaijLL | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:RomeroJ CJC | lld:pubmed |
| pubmed-article:2644824 | pubmed:author | pubmed-author:MirandaBB | lld:pubmed |
| pubmed-article:2644824 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2644824 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:2644824 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2644824 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2644824 | pubmed:pagination | 120-6 | lld:pubmed |
| pubmed-article:2644824 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:meshHeading | pubmed-meshheading:2644824-... | lld:pubmed |
| pubmed-article:2644824 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2644824 | pubmed:articleTitle | Converting enzyme inhibition in chronic renal failure. | lld:pubmed |
| pubmed-article:2644824 | pubmed:affiliation | Hospital l de Octubre, Madrid, Spain. | lld:pubmed |
| pubmed-article:2644824 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2644824 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2644824 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2644824 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2644824 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2644824 | lld:pubmed |
